ArticleCancer biomarkers : section A of Disease markers2025
Multi-omics pan-cancer analysis of monocyte to macrophage differentiation-associated (MMD) and its significance in hepatocellular carcinoma.
Article in Cancer biomarkers : section A of Disease markers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of prognostic biomarkers related to epithelial-mesenchymal transition and anoikis in hepatocellular carcinoma using transcriptomics and single-cell sequencing.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundMalignant tumors are serious diseases that endanger human health. Therefore, it is crucial to identify markers that facilitate tumor diagnosis and prognostic assessment.ObjectiveThis study analyzed the significance of Monocyte to macrophage differentiation-associated (MMD) in various tumors from multiple perspectives, to explore the possibility of using MMD as a novel tumor marker.MethodsUsing the R software, an examination of MMD levels was conducted across diverse human cancers and their influence on cancer outcomes. MMD methylation, mutations, and immune infiltration analyses of various tumors were performed. A Cox regression model was used to predict the survival rates of patients with hepatocellular carcinoma (HCC). Finally, MMD expression and function were validated in Hep-3B cells.ResultsMMD was aberrantly expressed in diverse tumors and can predict patient outcomes. Methylation and functional enrichment studies indicated possible function of MMD in tumor progression, whereas immune infiltration data suggested its involvement in tumor immune evasion. Cox regression analysis revealed that elevated MMD levels were independent predictors of HCC patient outcomes. The quantitative real-time polymerase chain reaction (qPCR) data demonstrated high MMD levels in Hep-3B cells, and its suppression impeded Hep-3B cell growth.ConclusionsMMD was abnormally expressed in various tumors and was closely associated with tumor prognosis. Thus, it had the potential to be used as a novel tumor marker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.